DUBAI, UAE  — June 20, 2026 — Beaufond PLC today announced a implementation & activation of US$112 capital program to expand its analytical and quality infrastructure across its flagship development facility and a network of partner contract manufacturing organizations (CMOs). The program equips both the core facility and selected partner sites with matched analytical instrumentation and a shared data system, with the aim of reducing the delays that typically arise when a manufacturing method moves from in-house development to a partner production site.

Addressing a Known Industry Bottleneck

Moving a validated analytical method from a sponsor’s development laboratory to a contract manufacturer’s production site is a routine part of pharmaceutical scale-up, and it is also a routine source of delay. Differences in instrumentation, software, and local data systems between sites can require re-validation work before a method already proven in-house can be used at the new location.

Beaufond’s program is designed to reduce that gap by installing the same instrument platforms and the same centralized data system at its core facility and at each partner site, so that a method developed in-house requires less rework before it can be used at a partner CMO.

Program Structure

The capital program covers two categories of investment:

• Core facility instrumentation — structural characterization, molecular analysis, and the central data system, based at Beaufond’s flagship development site & third party research locations.
• Partner-site analytical bays — dedicated chromatography, solid-state characterization, and inline process monitoring equipment installed at select partner CMO facilities.

Equipment installed at partner sites is owned by Beaufond and operated by Beaufond personnel under a Quality Agreement with each host CMO, consistent with the contractual framework set out in ICH Q7 for outsourced manufacturing. Each Quality Agreement defines the scope of Beaufond’s on-site activity, data handling, and audit rights, and operates alongside — not in place of — the CMO’s own quality system and regulatory obligations for its facility.

Anticipated Operational Benefits

• Faster method deployment: matched instrumentation across sites is intended to shorten the time between in-house validation and use at a partner facility.
• Earlier visibility into process variation: inline monitoring equipment is intended to allow review of reaction and crystallization data during synthesis, rather than only after a batch is complete.
• Reduced reagent and reference-standard consumption: acoustic, non-contact liquid handling reduces the sample volumes required for routine testing.
• Flexible allocation of testing capacity: because partner-site bays use the same instrument platforms and data system as the core facility, testing volume can in principle be redirected to another site during planned maintenance or a local disruption.

Beaufond Technical Team Comment

“This program reflects a straightforward engineering choice: when our quality teams and our partner manufacturers are working from the same instruments and the same data system, fewer things have to be re-checked, re-validated, or re-explained when a product moves from development to production. That is the problem this investment is built to solve.” — Beaufond PLC Executive Technical Team Management.

Implementation Timeline

Deployment is completed across the partner network over the program period., Site-specific Quality Agreements and facility risk assessments were completed on a site-by-site basis ahead of equipment installation.

About Beaufond PLC

Beaufond PLC is an international pharmaceutical and life sciences company operating across the Middle East, Europe, and Asia, with activities spanning pharmaceutical development and contract manufacturing partnerships.

Media & Communication Desk

Mr. Christopher Lynn  Email: media.relations@beaufond.com  |  Web: www.beaufond.com